Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: Results from NORDCAN and NOCCA databases

Maturitas

Volumn 72, Issue 1, 2012, Pages 56-60

  Koivisto Korander, R ^a   Martinsen, J I ^b   Weiderpass, E ^b,c,d,e   Leminen, A ^a   Pukkala, E ^f,g  

^a UNIVERSITY OF HELSINKI   (Finland)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c KAROLINSKA INSTITUTE   (Sweden)

^d FOLKHÄLSAN RESEARCH CENTER   (Finland)

^e UNIVERSITY OF TROMSØ   (Norway)

^f FINNISH CANCER REGISTRY   (Finland)

^g TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Endometrial stromal sarcoma; Leiomyosarcoma; NOCCA; NORDCAN; Standardized incidence ratio; Uterine sarcoma

Indexed keywords

ADULT; AGRICULTURAL WORKER; ARTICLE; CANCER INCIDENCE; CANCER RISK; DENMARK; ENDOMETRIUM SARCOMA; FEMALE; FINLAND; HUMAN; ICELAND; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MENOPAUSE; NONMEDICAL OCCUPATIONS; NORWAY; ONSET AGE; SHOE AND LEATHER WORKER; TEACHER; UTERINE LEIOMYOSARCOMA; UTERUS SARCOMA;

ADULT; ANIMALS; DENMARK; DUST; FEMALE; FINLAND; HUMANS; INCIDENCE; LEIOMYOSARCOMA; MENOPAUSE; MIDDLE AGED; NORWAY; OCCUPATIONAL EXPOSURE; RISK FACTORS; SARCOMA, ENDOMETRIAL STROMAL; SWEDEN;

ANIMALIA;

EID: 84859533554     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2012.01.021     Document Type: Article

References (35)

1. McMeekin DS. Sarcoma of the uterus. In: DiSaia G, editor. Clinical gynecologic oncology. seventh ed. Philadelphia: Mosby Elsevier; 2007.
2. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12(November-December (6)):687-90.
3. Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur J Cancer 1997;33(May (6)):907-11.
4. Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009;54(February (3)):355-64.
5. Schwartz SM, Weiss NS, Daling JR, et al. Exogenous sex hormone use, correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus. Cancer 1996;77(February (4)):717-24.
6. Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002;20(June (11)):2758-60.
7. Arenas M, Rovirosa A, Hernandez V, et al. Uterine sarcomas in breast cancer patients treated with tamoxifen. Int J Gynecol Cancer 2006;16(March-April (2)):861-5.
8. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004;93(April (1)):204-8.
9. Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 1986;76(March (3)):399-402.
10. Kokawa K, Nishiyama K, Ikeuchi M, et al. Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990-2003). Int J Gynecol Cancer 2006;16(May-June (3)):1358-63.
11. Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001. Gynecol Oncol 2008;111(October (1)):74-81.
12. Statistics Denmark Nordic statistical yearbook 2010. Copenhagen: Nordic Council of Ministers; 2010.
13. Pukkala E, Martinsen JI, Lynge E, et al. Occupation and cancer - follow-up of 15 million people in five Nordic countries. Acta Oncol 2009;48(5):646-790.
14. Engholm G, Ferlay J, Christensen N, et al. NORDCAN - a Nordic tool for cancer information, planning, quality control and research. Acta Oncol 2010;49(June (5)):725-36.
15. Lund EM, Clemmesen IH, Storm HH. Survey of Nordic cancer registries. In: ANCR. Survey of Nordic cancer registries. Copenhagen, Denmark; 2000. p. 7-18. http://www.ancr.nu/survey.asp.
16. Engholm G, Ferlay J, Christensen N, et al. NORDCAN: cancer incidence, mortality, prevalence and prediction in the Nordic countries, Version 3.7; 2010.
17. Jaakkola S, Lyytinen HK, Pukkala E, Ylikorkala O. Use of estradiol-progestin therapy associates with increased risk for uterine sarcomas. Gynecol Oncol 2011;April.
18. Hemminki E, Kyyronen P, Pukkala E. Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995-2005. Maturitas 2008;61(December (4)):299-304.
19. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(July (3)):321-33.
20. Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.
21. D'Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum Pathol 2009;40(November (11)):1571-85.
22. Cramer DW. Epidemiologic aspects of early menopause and ovarian cancer. Ann N Y Acad Sci 1990;592:363-75 [discussion 390-4]. (Pubitemid 20273238)
23. Lope V, Perez-Gomez B, Aragones N, et al. Occupational exposure to chemicals and risk of thyroid cancer in Sweden. Int Arch Occup Environ Health 2009;82(January (2)):267-74.
24. Mikoczy Z, Schutz A, Stromberg U, Hagmar L. Cancer incidence and specific occupational exposures in the Swedish leather tanning industry: a cohort based case-control study. Occup Environ Med 1996;53(July (7)):463-7.
25. Kauppinen T, Heikkila P, Plato N, et al. Construction of job-exposure matrices for the Nordic Occupational Cancer Study (NOCCA). Acta Oncol 2009;48(5):791-800.
26. Blair A, Zahm SH. Agricultural exposures and cancer. Environ Health Perspect 1995;103(November (Suppl. 8)):205-8.
27. Blair A, Freeman LB. Epidemiologic studies in agricultural populations: observations and future directions. J Agromed 2009;14(2):125-31.
28. Laakkonen A, Kyyronen P, Kauppinen T, Pukkala EI. Occupational exposure to eight organic dusts and respiratory cancer among Finns. Occup Environ Med 2006;63(November (11)):726-33.
29. Weiderpass E, Pukkala E, Vasama-Neuvonen K, et al. Occupational exposures and cancers of the endometrium and cervix uteri in Finland. Am J Ind Med 2001;39(June (6)):572-80.
30. Pukkala E. Cancer risk by social class and occupation: a survey of 109,000 cancer cases among Finnish of working age. Contributions in epidemiology biostatistics, vol. 7. Basel: Karger; 1995.
31. Hinkula M, Pukkala E, Kyyronen P, Kauppila A. Grand multiparity and incidence of endometrial cancer: a population-based study in Finland. Int J Cancer 2002;98(April (6)):912-5.
32. Kvale G, Heuch I, Ursin G. Reproductive factors and risk of cancer of the uterine corpus: a prospective study. Cancer Res 1988;48(November (21)):6217-21.
33. Schwartz SM, Weiss NS, Daling JR, et al. Incidence of histologic types of uterine sarcoma in relation to menstrual and reproductive history. Int J Cancer 1991;49(September (3)):362-7.
34. Albrektsen G, Heuch I, Tretli S, Kvale G. Is the risk of cancer of the corpus uteri reduced by a recent pregnancy? A prospective study of 765,756 Norwegian women. Int J Cancer 1995;61(May (4)):485-90.
35. Wolfe WS, Sobal J, Olson CM, Frongillo Jr EA, Williamson DF. Parity-associated weight gain and its modification by sociodemographic and behavioral factors: a prospective analysis in US women. Int J Obes Relat Metab Disord 1997;21(September (9)):802-10.